Continuous Manufacturing: Cost, Lack Of Know-How Have Deterred Generic Firms, Prof Says
Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.
You may also be interested in...
US FDA-related legislation among the bills moving during the lame duck session of Congress.
The COVID-19 pandemic has prompted the ICH to delay by six months its efforts to develop Q13 guideline on continuous manufacturing, now not expected until May 2022.
House tries again to promote advanced technology for the return of pharmaceutical manufacturing to the US in post-COVID-19 era.